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Abstract: Fibroblast growth factor 21 (FGF21) is a human metabolic hormone whose effects include
modification of macronutrient preference and energy homeostasis. In animal models, FGF21 has been
shown to have beneficial effects on cardiometabolic outcomes, Alzheimer’s disease risk and lifespan.
In this study, the single-nucleotide polymorphism rs838133 in the FGF21 gene region was leveraged
to investigate the potential clinical effects of targeting FGF21. The FGF21 G allele was associated with
lower intakes of total sugars and alcohol, and higher intakes of protein and fat as well as favourable
with lipid levels, blood pressure traits, waist-to-hip ratio, systemic inflammation, cardiovascular
outcomes, Alzheimer’s disease risk and lifespan. These findings may be used to anticipate the effects
of pharmacologically increasing FGF21 signalling.
Keywords: alcohol; cardiovascular disease; fibroblast growth factor 21; macronutrients; sugar;
mendelian randomization
1. Introduction
Fibroblast growth factor 21 (FGF21) is a human metabolic hormone that is expressed in
the liver [1]. The effects of FGF21 include altering of macronutrient preference and energy
homeostasis [1–3]. Increased circulating FGF21 decreases the consumption of sweets, sugar
and alcohol [2,4,5], and indirectly increases protein intake by suppressing sugar consump-
tion [6]. In rodents and non-human primates, FGF21 treatment has beneficial effects on
cardiometabolic outcomes, such as reduction in fat mass and alleviation of hyperglycaemia,
insulin resistance, dyslipidaemia, and cardiovascular diseases [7]. Furthermore, FGF21
has been implicated in protecting against Alzheimer’s disease [8], as well as improving
lifespan [9]. However, studies investigating the association between circulating FGF21 and
these clinical outcomes in humans have been inconclusive [7,10]. To investigate this further,
we aimed to leverage human genetic data within the Mendelian randomization paradigm
to investigate the associations of a common allele in the FGF21 gene with cardiometabolic
outcomes, Alzheimer’s disease and lifespan [11].
2. Materials and Methods
We used the single-nucleotide polymorphism rs838133 in the FGF21 gene region, previ-
ously shown to be associated with intake of macronutrients, alcohol and sweets [10,12], to
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assess potential effects of increasing FGF21 concentrations. Publicly available summary-
level data for the associations of the FGF21 variant with macronutrient and alcohol intake
and other outcomes were obtained from the UK Biobank cohort and genome-wide asso-
ciation study consortia [13–24]. Details of the outcome datasets used in this study are
provided in Table S1. For cardiometabolic diseases, we meta-analysed the estimates from
the different data sources using inverse-variance models with fixed effects.
Only summary-level (i.e., aggregated) data were analysed in this study, for which
appropriate ethical approval and participant consent had previously been obtained. The
present Mendelian randomization analyses were approved by the Swedish Ethical Review
Authority. We confirm that we have read the Journal’s position on issues involved in ethical
publication and affirm that this work is consistent with those guidelines.
3. Results
The G (major) allele of rs838133 in the FGF21 gene region was associated with lower
intakes of total sugars and alcohol, and higher intakes of protein and fat (Figure 1), consis-
tent with the expected effect of an increase in FGF21 concentration. We scaled all results
per additional G allele to mimic the effect of elevated FGF21 concentrations.
Figure 1. Associations of the FGF21 rs838133 G allele with macronutrient intake, anthropometric and
cardiometabolic traits, liver enzymes and metabolites, and lifespan. The outcomes are in standard
deviation units except for lifespan (in years). CI: confidence interval.
The FGF21 rs838133 G allele was associated with greater body mass index, body fat
percentage and waist and hip circumferences, but with lower waist-to-hip ratio (Figure 1).
Additionally, the G allele was associated with lower low-density lipoprotein cholesterol
and triglyceride concentrations, lower systolic and diastolic blood pressure, and lower
C-reactive protein concentrations, but was not associated with fasting glucose or fasting
insulin concentrations (Figure 1). There was a positive association of the FGF21 rs838133 G
allele with the liver enzyme alkaline phosphatase, but a negative association with aspartate
aminotransferase, gamma glutamyltransferase, and direct and total bilirubin concentrations
(Figure 1). There was suggestive evidence of a positive association between the FGF21
rs838133 G allele and lifespan (based on parental lifespan) (Figure 1).
In analyses of cardiovascular diseases, the FGF21 rs838133 G allele was strongly
associated with a reduced risk of venous thromboembolism, and had suggestive inverse
associations with coronary artery disease, heart failure, and ischemic stroke (Figure 2).
There was a suggestive association of the FGF21 rs838133 G allele with reduced risk of
Nutrients 2021, 13, 1504 3 of 5
Alzheimer’s disease (based on clinically diagnosed Alzheimer’s disease and Alzheimer’s
disease by proxy cases and their corresponding controls), but no association with type 2
diabetes (Figure 2).
Figure 2. Associations of the FGF21 rs838133 G allele with cardiometabolic diseases and Alzheimer’s
disease. CI: confidence interval; OR: odds ratio.
4. Discussion
This work leveraged human genetic data to provide insight into the broad metabolic
and clinical effects of the major (G) allele of rs838133 in the FGF21 gene. Our results support
previously reported associations between the FGF21 rs838133 variant with macronutrient
and alcohol intake, lipid levels, blood pressure, waist-to-hip ratio, and liver enzymes as
well as the lack of association with type 2 diabetes in the UK Biobank cohort [10]. It should
be noted that the previous study used the minor (A) allele of the rs838133 variant as the
effect allele [10] and thus showed associations in the opposite direction to our findings.
The present study went further to provide novel evidence that the major allele of rs838133
in the FGF21 gene was associated with decreased systemic inflammation (estimated by
C-reactive protein concentration). We also identified a potential beneficial effect of the
major allele at FGF21 rs838133 on cardiovascular outcomes, with the strongest association
for venous thromboembolism, as well as on Alzheimer’s disease and lifespan.
These findings inform on the potential effects of pharmacologically increasing FGF21
concentrations or signalling. The limitations of this study should also be acknowledged.
Critically, it is possible that some of the identified associations may be attributable to genetic
confounding, where the FGF21 genetic variant also has pleiotropic associations unrelated
to FGF21. As summary genetic association data for circulating FGF21 concentrations were
not available, we could not perform colocalization analysis to explore this possibility [25].
Furthermore, the outcomes that we studied were determined by the availability of corre-
sponding large-scale genetic association summary data. As such, it was not possible to
perform analyses for other relevant traits, such as non-alcoholic steatohepatitis.
5. Conclusions
In summary, we used a major allele of rs838133 in the FGF21 gene to identify evidence
for its effects on macronutrient and alcohol intake as well as favourable effects on a range
of cardiometabolic outcomes, Alzheimer’s disease and lifespan. This work anticipates the
effects of pharmacologically increasing FGF21 signalling.
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.3390/nu13051504/s1, Table S1: Data sources for the outcome phenotypes included in the present
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